Results 161 to 170 of about 77,084 (260)

From Oxidative Stress to Bioenergetic Remodeling: Translational Value and Clinical Implications of Exogenous ATP in PARP Inhibitor-Associated Liver Injury [Letter]. [PDF]

Drug Des Devel Ther
Shang M, Ge X.
europepmc   +1 more source

The DNA/RNA Helicase SETX Maintains R‐Loop Homeostasis to Promote Chemoresistance in Ovarian Cancer

Cancer Science, EarlyView.
SETX maintains R‐loop homeostasis by resolving excessive R‐loops, thereby promoting tumor initiation and chemoresistance. Deficiency of SETX leads to accumulation of unsolved pathological R‐loops, resulting in irreparable DNA damage and ultimately leading to tumor suppression and chemosensitivity.
Zi‐Wei Hu, Tu‐Nan Xu, Zi‐Ying Wang, Xin Zheng, Duan‐Yong Feng, Xiao‐Min Wang, Er‐Suo Jin, Ming Ren, Xiao‐Min Yang, Xian‐Chao Zhang, Xuan Che, Wei‐Wei Pan, Zha‐Jun Zhan, Shu‐Qun Cheng   +13 more
wiley   +1 more source

PARP Inhibitors in Lung Cancer [PDF]

Journal of Thoracic Oncology, 2012
openaire   +2 more sources

CDK4/6 Inhibitors and Curcumin Synergistically Suppress HER2− Breast Cancer via Lethal ROS and Inhibition of Metastasis

Cancer Science, EarlyView.
Schematic illustrating that CDK4/6 inhibitors combined with curcumin induce lethal ROS accumulation by disrupting redox balance, downregulating GPX4, and depleting glutathione, leading to DNA damage and lipid peroxidation. This oxidative stress triggers tumor cell death and suppresses EMT‐driven migration.
Chenyu Wang, Yiqin Zou, Chunyu Chang, Siyue Liu, Xiankun Ke, Liang Hu, Di Wang, Yukang Lu, Shiwen Luo, Sijian Huang, Yilan Hu, Wenqi Yu, Aiping Deng, Ming Yue, Jue Jiang   +14 more
wiley   +1 more source

Mechanisms of PARP Inhibitor Resistance: From Replication Gap Biology and Transcription-Replication Conflicts to PROTAC-Based Next-Generation Strategies. [PDF]

Environ Mol Mutagen
Abinawanto, Sophian A.
europepmc   +1 more source

Real‐World Germline Variant Landscape and Clinical Management in Korean Patients Tested for Suspected Hereditary Cancer

Cancer Science, EarlyView.
In 5829 Korean patients undergoing hereditary cancer germline testing, 987 (16.9%) carried pathogenic/likely pathogenic variants. Post‐test management varied substantially across gene groups, while variant reclassification identified 46 additional carriers, underscoring the need for gene‐specific management and structured recontact.
Min‐Chae Kang, Ha‐Eun Lee, Sang‐Yoon Park, Seeyoun Lee, So‐Youn Jung, Myong Cheol Lim, Han‐Sung Kang, Chang Ahn Seol, Jun‐Ha Jang, Sang Myung Woo, Jae Young Joung, Wonyoung Choi, Sung Chan Park, Sun‐Young Kong   +13 more
wiley   +1 more source

Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice. [PDF]

Br J Cancer
Macdonald CJ, McWhirter A, Vaidyanathan A, Ferguson MJ, Eberl HC, Stronach EA, Sawers L, Smith G.   +7 more
europepmc   +1 more source

Expanding the horizons of PARP inhibitors [PDF]

Nature Reviews Cancer, 2010
openaire   +2 more sources

Leveraging venetoclax‐induced autophagy to enhance AUTAC‐mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Ahmed M. Elshazly, Nayyerehalsadat Hosseini, Janakiram R. Vangala, Xiaoyan Hu, Steven Grant, Senthil K. Radhakrishnan   +5 more
wiley   +1 more source

Methyl 4‐O‐Demethylbarbatate Destabilises HIF‐1α and Enhances Temozolomide Sensitivity in Glioma Cells

Cell Proliferation, EarlyView.
The lichen‐derived metabolite methyl 4‐O‐demethylbarbatate (Me‐4‐O‐DBA) suppresses glioma stemness, motility, and metabolic plasticity through inhibition of HIF‐1α signaling and synergistically enhances temozolomide activity, highlighting a potential strategy to target stemness‐driven therapeutic resistance in glioma.
Rui Zhou, Mücahit Varlı, Rundong Liu, Jieun Yu, Hyung‐Ho Ha, Jae‐Seoun Hur, Sang Kyum Kim, Hahyun Park, Hangun Kim   +8 more
wiley   +1 more source